The application of biologics in clinical practice allows immunological observations under real-life conditions. In a new article in the Journal of Investigative Dermatology, Bakker et al. (2021) use deep immune cell phenotyping to demonstrate how dupilumab acts in a targeted fashion on skin-homing T cells, the driver cells of atopic dermatitis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jid.2021.02.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eosinophilic gastrointestinal disorders: a narrative review on clinical perspectives and research gaps in the Asian context.
Transl Gastroenterol Hepatol
August 2024
Allergy Service, Paediatric Medicine, Kandang Kerbau Women's and Children's Hospital (KKH), Singapore, Singapore.
Article Synopsis
- Eosinophilic gastrointestinal disorders (EGID) include conditions like eosinophilic esophagitis (EoE), but much of the existing research has focused on populations in Europe and North America, highlighting a need for more studies on Asian populations.
- This review aims to summarize recent developments in EGID, focusing on the unique disease characteristics and responses to treatment in Asian patients, as compared to Western populations.
- There is a critical lack of comprehensive data on EGID in Asia, emphasizing the need for collaborations to improve research quality and representation in this region.
Asthma Biologics: Lung Function, Steroid-Dependence, and Exacerbations.
Immunol Allergy Clin North Am
November 2024
Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA; Division of Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Article Synopsis
- The past two decades have seen significant advancements in asthma treatment with the development of targeted biologic therapies.
- There are currently six monoclonal antibodies designed to target specific inflammatory mediators involved in asthma, allowing for more personalized treatment options.
- These therapies include omalizumab (anti-IgE), mepolizumab and reslizumab (anti-IL-5), benralizumab (IL-5 receptor antagonist), dupilumab (IL-4 receptor antagonist), and tezepelumab (anti-thymic stromal lymphopoietin).
Despite the prevalence and the impact on quality of life of dermatological indications, drug products to treat such conditions have rarely been blockbusters. The prevailing perception of a limited commercial potential of dermatological drug products has restricted innovation and encouraged a more conservative development approach. For example, the focus was on repurposing/reformulation of existing active pharmaceutical ingredients (APIs) specifically for the topical delivery route.
View Article and Find Full Text PDFChoosing the Right Biologic for the Right Patient With Severe Asthma.
Chest
September 2024
National Jewish Health, Denver, CO.
In this instalment of the How I Do It series on severe asthma, we tackle the clinical conundrum of choosing the right biologic for the right patient with severe asthma. With six biologics now approved for use in this area comprising four different targeting strategies (anti-Ig E: omalizumab; anti-IL-5 and anti-IL-5-receptor: mepolizumab, reslizumab, and benralizumab; anti-IL-4-receptor: dupilumab; anti-thymic stromal lymphopoietin: tezepelumab), this question is increasingly complex. Recognizing that no head-to-head trial has compared biologics, we based our review on the expected effects of inhibiting different aspects of type 2 airway inflammation, supported whenever possible by clinical trial and real-world data.
View Article and Find Full Text PDFDiagnosis, management and therapeutic options for eosinophilic esophagitis.
Curr Opin Allergy Clin Immunol
June 2024
Department of Medicine and Medical Therapeutics, University of Pavia.
Article Synopsis
- Eosinophilic esophagitis (EoE) is a chronic condition that causes tissue damage in the esophagus, impacting quality of life; recent advances focus on diagnosing and managing the disease.
- New diagnostic methods classify EoE into three distinct endotypes based on inflammatory features and symptoms, which helps tailor treatment.
- Two new medications, oro-dispersible budesonide and dupilumab, target EoE specifically, and a collaborative approach between gastroenterologists and allergist-immunologists is essential for effective management of the disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!